Amneal Pharmaceuticals (AMRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Critical company metrics and information
Share Price
$8.03Market Cap
$2.49 BillionTotal Outstanding Shares
309.84 Million SharesTotal Employees
7,700Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.amneal.com
Historical Stock Splits
If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution Date | Split Amount |
---|---|
August 26, 2013 | 1-for-25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities, Continuing | $-251.42 Million |
Net Cash Flow, Continuing | $-17.20 Million |
Net Cash Flow From Investing Activities | $-78.63 Million |
Net Cash Flow From Operating Activities, Continuing | $312.84 Million |
Exchange Gains/Losses | $-58,000.00 |
Net Cash Flow From Financing Activities | $-251.42 Million |
Net Cash Flow From Operating Activities | $312.84 Million |
Net Cash Flow | $-17.26 Million |
Net Cash Flow From Investing Activities, Continuing | $-78.63 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $2.68 Billion |
Research and Development | $182.53 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $4.73 Million |
Income Tax Expense/Benefit | $23.32 Million |
Gross Profit | $947.39 Million |
Income/Loss From Continuing Operations Before Tax | $-123.16 Million |
Net Income/Loss | $-146.48 Million |
Operating Expenses | $759.67 Million |
Diluted Earnings Per Share | $-0.85 |
Benefits Costs and Expenses | $2.80 Billion |
Cost Of Revenue | $1.73 Billion |
Preferred Stock Dividends And Other Adjustments | $4.73 Million |
Operating Income/Loss | $187.73 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $37.98 Million |
Nonoperating Income/Loss | $-310.88 Million |
Other Operating Expenses | $120.38 Million |
Costs And Expenses | $2.80 Billion |
Basic Earnings Per Share | $-0.86 |
Basic Average Shares | $331.46 Million |
Diluted Average Shares | $328.54 Million |
Net Income/Loss Attributable To Parent | $-179.73 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-184.45 Million |
Income/Loss From Continuing Operations After Tax | $-146.48 Million |
Selling, General, and Administrative Expenses | $456.75 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities | $3.49 Billion |
Wages | $64.90 Million |
Equity Attributable To Parent | $-93.43 Million |
Other Current Assets | $916.93 Million |
Other Non-current Liabilities | $5.15 Million |
Assets | $3.46 Billion |
Accounts Payable | $235.00 Million |
Fixed Assets | $431.02 Million |
Current Assets | $1.51 Billion |
Inventory | $596.36 Million |
Noncurrent Liabilities | $2.40 Billion |
Other Non-current Assets | $736.48 Million |
Noncurrent Assets | $1.95 Billion |
Temporary Equity | $59.89 Million |
Equity | $-93.57 Million |
Current Liabilities | $1.10 Billion |
Liabilities And Equity | $3.46 Billion |
Equity Attributable To Noncontrolling Interest | $-135,000.00 |
Long-term Debt | $2.39 Billion |
Other Current Liabilities | $795.31 Million |
Intangible Assets | $780.19 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.